Faron Pharmaceuticals Ltd: PDMR Dealing
Faron Pharmaceuticals Ltd | Company announcement | January 13, 2026 at 18:00:00 EET
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Mr. Jurriaan Dekkers, Chief Financial Officer of the Company, sold 4,000 ordinary shares in Faron at price of £1.822 per share on 12 January 2026.
Further details are set out in the Notification of Dealing Form below.
| PDMR | Holding prior to sale | Number of ordinary shares sold | Resultant interest in ordinary shares in the Company | Resultant percentage of voting rights in the Company |
| Jurriaan Dekkers | 4,000 | 4,000 | 0 | 0.0% |
For more information, please contact:
| IR Partners, Finland (Media) Kare Laukkanen | +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi |
| FINN Partners, US (Media) Alyssa Paldo | +1 847 791-8085 alyssa.paldo@finnpartners.com |
| Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner | +44 (0) 207 213 0880 |
| Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä | +358 (0)40 555 4727 +358 (0)50 553 8990 |
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Jurriaan Dekkers | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Chief Financial Officer | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | Faron Pharmaceuticals Ltd. | |||
| b. | LEI | 7437009H31TO1DC0EB42 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary Shares ISIN: FI4000153309 | |||
| b. | Nature of the transaction | Sale of Ordinary Shares | |||
| Price(s) per share (p) | Volume(s) | ||||
| £1.822 | 4,000 | ||||
| d. | Aggregated information Volume Price | 4,000 £1.822 | |||
| e. | Date of the transaction | 12/01/2026 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||